As copied from a hidden thread:
A US company valued at $250m (including $100m cash and a free carried commercialisation grant of $231m).
We're now a realistic proposition to be gobbled up by a Gilead, Vertex or whoever.
If the chances of LANI approval are very high, US mid Pharma would have to now consider this a $1bn free carry.